Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Eris LifesciencesBOM:540596 +0.42%92 EV-to-EBITDA is 18.19 as of Aug. 29, 2026, which is 6% below its 10-year median of 19.39. GuruFocus rates BOM:540596 with a GF Score™ of 92/100 and a GF Value™ of ₹1,658.74 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 733 Drug Manufacturers companies, Eris Lifesciences ranks worse than 63.17% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Eris Lifesciences's enterprise value is ₹205,280 Mil.
Eris Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 was ₹11,286 Mil. Therefore, Eris Lifesciences's EV-to-EBITDA for today is 18.19.
The historical rank and industry rank for Eris Lifesciences's EV-to-EBITDA or its related term are showing as below:
BOM:540596'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 12.88 Med: 19.39 Max: 34.48
Current: 18.19
During the past 13 years, the highest EV-to-EBITDA of Eris Lifesciences was 34.48. The lowest was 12.88. And the median was 19.39.
BOM:540596's EV-to-EBITDA is ranked worse than 63.17% of 733
companies
in the Drug Manufacturers industry
Industry Median: 13.06
vs BOM:540596: 18.19
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Eris Lifesciences's PE Ratio (TTM) for today is calculated as:
Eris Lifesciences's share price for today is ₹1317.10.
Eris Lifesciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹46.960.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Eris Lifesciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Eris Lifesciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Eris Lifesciences EV-to-EBITDA vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Eris Lifesciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Eris Lifesciences's EV-to-EBITDA falls into.
Eris Lifesciences's current Enterprise Value is ₹205,280 Mil.
Eris Lifesciences's EBITDA for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹11,286 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Eris Lifesciences (BOM:540596) has a EV-to-EBITDA of 18.19 as of Aug. 29, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eris Lifesciences. This is near median its historical median of 19.39. Over the past decade, Eris Lifesciences' EV-to-EBITDA has ranged from 12.88 to 34.48. According to the industry distribution chart, Eris Lifesciences ranks #463 out of 733 companies in the Drug Manufacturers industry, placing it in the top 63.2%.
Is Eris Lifesciences' EV-to-EBITDA too high?
Eris Lifesciences' current EV-to-EBITDA of 18.19 is near median its 10-year median of 19.39. Over the past 10 years, this metric has ranged from a low of 12.88 to a high of 34.48. The Drug Manufacturers industry median EV-to-EBITDA is 13.06. Eris Lifesciences' value of 18.19 is 39.3% above this industry median. Based on the distribution chart, Eris Lifesciences ranks #463 out of 733 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Eris Lifesciences has a GF Score™ of 92/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Eris Lifesciences' EV-to-EBITDA compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Eris Lifesciences ranks #463 out of 733 companies for EV-to-EBITDA. This places Eris Lifesciences in the lower half of its industry. The industry median EV-to-EBITDA is 13.06. Eris Lifesciences' value of 18.19 is 39.3% above this benchmark. Historically, Eris Lifesciences' own EV-to-EBITDA has ranged from 12.88 to 34.48 over the past decade. While the company's 10-year median is 19.39 vs. the industry median of 13.06, Eris Lifesciences has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Drug Manufacturers company?
The median EV-to-EBITDA among Drug Manufacturers companies is 13.06, based on 733 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Eris Lifesciences's current EV-to-EBITDA of 18.19 is 39.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Eris Lifesciences. For the Drug Manufacturers industry, the median EV-to-EBITDA is 13.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Eris Lifesciences's current EV-to-EBITDA is 18.19, which is near median its own 10-year median of 19.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eris Lifesciences stock overvalued right now?
Based on GuruFocus' analysis, Eris Lifesciences (BOM:540596) is currently considered Modestly Undervalued. The stock's GF Value™ is ₹1,658.74, compared to a current price of ₹1,317.10 — trading 20.6% below its estimated fair value. The current EV-to-EBITDA is 18.19, which is near median its 10-year median of 19.39 and 39.3% above the Drug Manufacturers industry median of 13.06. Eris Lifesciences' overall GF Score™ is 92/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Eris Lifesciences (BOM:540596), the current EV-to-EBITDA is 18.19 as of Aug. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Eris Lifesciences (BOM:540596) Overvalued in 2026?
Based on GuruFocus' analysis, Eris Lifesciences stock appears to be undervalued.
The current stock price of ₹1,317.10 is trading 20.6% below its estimated GF Value™ of ₹1,658.74.
GuruFocus considers Eris Lifesciences to be Modestly Undervalued.
Key valuation signals for BOM:540596:
EV-to-EBITDA: 18.19 (near median its 10-year median of 19.39)
GF Value™: ₹1,658.74 vs. price of ₹1,317.10 (20.6% below fair value)
Industry Position: 39.3% above the Drug Manufacturers median (#463 of 733)
No single metric tells the full story. See the BOM:540596 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Eris Lifesciences Ltd is an India-based company engaged in the manufacturing and sale of branded pharmaceutical formulations. It focuses on Lifestyle therapies such as Diabetes Care, Cardiac Care, Nutrition, Central Nervous System, and others. The company operates in a single segment that is pharmaceuticals. Some of its brands include Glimisave, Cyblex, Eritel, Atorsave and Crevast. The company works basically within India and International with the majority of revenue from India.
92GF Score
Get the complete analysis for BOM:540596
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540596 has been successfully added to your 
